| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.90 [0.81, 1.01] | | < 1 | | 0% | 3 studies (3/-) | 96.9 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.28 [0.85, 1.92] | | < 1 | | 93% | 3 studies (3/-) | 12.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 0.75 [0.27, 2.10] | | > 1 | | 94% | 3 studies (3/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.46 [0.20, 1.08] | | < 1 | | 0% | 2 studies (2/-) | 96.3 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.32 [0.03, 4.02] | | < 1 | | 99% | 2 studies (2/-) | 80.9 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.29 [0.44, 3.78] | | < 1 | | 0% | 2 studies (2/-) | 32.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.58 [0.07, 5.15] | | < 1 | | 96% | 2 studies (2/-) | 68.7 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 0.31 [0.09, 1.08] | | < 1 | | 94% | 3 studies (3/-) | 96.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.31 [0.21, 0.47] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 2.84 [0.29, 27.42] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.55 [0.24, 1.28] | | < 1 | | 0% | 1 study (1/-) | 91.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.42 [0.05, 3.19] | | < 1 | | 0% | 3 studies (3/-) | 79.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.37 [0.11, 1.24] | | < 1 | | 84% | 3 studies (3/-) | 94.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.35 [0.04, 3.02] | | < 1 | | 74% | 2 studies (2/-) | 83.0 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.73 [0.09, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.16 [0.01, 3.11] | | < 1 | | 0% | 1 study (1/-) | 88.6 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.47 [0.13, 1.71] | | < 1 | | 61% | 3 studies (3/-) | 87.4 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.50 [0.17, 1.46] | | < 1 | | 46% | 3 studies (3/-) | 89.8 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.73 [0.09, 6.31] | | < 1 | | 0% | 2 studies (2/-) | 61.0 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.47 [0.13, 1.79] | | < 1 | | 78% | 3 studies (3/-) | 86.4 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.59 [0.20, 12.36] | | < 1 | | 0% | 3 studies (3/-) | 32.9 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.43 [0.23, 25.98] | | < 1 | | 34% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.20 [0.01, 4.07] | | < 1 | | 77% | 2 studies (2/-) | 85.1 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.33 [0.05, 2.28] | | < 1 | | 75% | 3 studies (3/-) | 86.7 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 2.06] | | < 1 | | 90% | 3 studies (3/-) | 94.0 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.40 [0.02, 8.98] | | < 1 | | 78% | 2 studies (2/-) | 71.7 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.63 [0.08, 5.09] | | < 1 | | 44% | 3 studies (3/-) | 66.5 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 5.91 [0.29, 118.71] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.44 [0.11, 18.83] | | < 1 | | 0% | 2 studies (2/-) | 39.1 % | low | not evaluable | high | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.34 [0.02, 6.97] | | < 1 | | 77% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.42 [0.03, 5.35] | | < 1 | | 65% | 2 studies (2/-) | 74.5 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.22 [0.01, 5.00] | | < 1 | | 79% | 2 studies (2/-) | 82.6 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.22 [0.17, 8.73] | | < 1 | | 0% | 2 studies (2/-) | 42.0 % | low | not evaluable | high | non important | - |
